AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: LON:AZN
- CUSIP: N/A
- Web: www.astrazeneca.com/
Capitalization:- Market Cap: £56.56 billion
- Outstanding Shares: 1,266,000,000
Average Prices:- 50 Day Moving Avg: GBX 4,863.89
- 200 Day Moving Avg: GBX 4,868.98
- 52 Week Range: GBX 3,996 - GBX 5,520
P/E:- Trailing P/E Ratio: 14.65
- P/E Growth: 3.40
Sales & Book Value:- Annual Revenue: £21.74 billion
- Price / Sales: 2.60
- Book Value: GBX 10.78 per share
- Price / Book: 4.14
Dividend:
Profitability:- EBIDTA: £5.91 billion
- Net Margins: 8.83%
- Return on Equity: 14.36%
- Return on Assets: 2.84%
Misc:- Average Volume: 2.19 million shs.
Frequently Asked Questions for AstraZeneca plc (LON:AZN)
What is AstraZeneca plc's stock symbol?
AstraZeneca plc trades on the London Stock Exchange (LON) under the ticker symbol "AZN."
How often does AstraZeneca plc pay dividends? What is the dividend yield for AstraZeneca plc?
AstraZeneca plc announced a dividend on Thursday, July 27th. Investors of record on Thursday, August 10th will be given a dividend of GBX 68.90 per share on Monday, September 11th. This represents a dividend yield of 1.35%. The ex-dividend date is Thursday, August 10th. The official announcement can be accessed at this link. View AstraZeneca plc's Dividend History.
Where is AstraZeneca plc's stock going? Where will AstraZeneca plc's stock price be in 2017?
20 equities research analysts have issued 12 month price targets for AstraZeneca plc's stock. Their forecasts range from GBX 3,900 to GBX 6,500. On average, they anticipate AstraZeneca plc's share price to reach GBX 4,951.80 in the next year. View Analyst Ratings for AstraZeneca plc.
Who are some of AstraZeneca plc's key competitors?
Some companies that are related to AstraZeneca plc include GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Company (BMY), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), GlaxoSmithKline plc (GSK), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Akorn (AKRX), Taro Pharmaceutical Industries (TARO), Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Amicus Therapeutics (FOLD) and Horizon Pharma PLC (HZNP).
Who are AstraZeneca plc's key executives?
AstraZeneca plc's management team includes the folowing people:
- Pascal Soriot, Executive Director and Chief Executive Officer
- Marc Dunoyer, Executive Director, Chief Financial Officer
- Fiona Cicconi, Executive Vice-President, Human Resources
- Sean Bohen M.D., Ph.D., Chief Medical Officer, Executive Vice President - Global Medicines Development
- Pam P. Cheng, Executive Vice President - Operations and Information Technology
- Ruud Dobber, Executive Vice President, North America
- Bahija Jallal Ph.D., Executive Vice President, MedImmune
- Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
- Menelas Pangalos, Executive Vice President - IMED Biotech Unit and Global Business Development
- Leon Wang, Executive Vice President - Asia Pacific
How do I buy AstraZeneca plc stock?
Shares of AstraZeneca plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is AstraZeneca plc's stock price today?
One share of AstraZeneca plc stock can currently be purchased for approximately GBX 4,467.50.
MarketBeat Community Rating for AstraZeneca plc (LON AZN)MarketBeat's community ratings are surveys of what our community members think about AstraZeneca plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for AstraZeneca plc (LON:AZN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Sell Ratings, 8 Hold Ratings, 9 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.30) |
| Consensus Price Target: | GBX 4,951.80 |
Analysts' Ratings History for AstraZeneca plc (LON:AZN)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 8/9/2017 | J P Morgan Chase & Co | Set Price Target | Neutral | GBX 4,200 |  |
| 8/9/2017 | Investec | Upgrade | Hold -> Buy | GBX 5,000 -> GBX 4,900 | |
| 8/8/2017 | HSBC Holdings plc | Set Price Target | Sell | GBX 4,100 | |
| 8/7/2017 | Barclays PLC | Reiterated Rating | Overweight | GBX 5,500 | |
| 8/3/2017 | Deutsche Bank AG | Lower Price Target | Buy | GBX 5,700 -> GBX 5,300 | |
| 8/2/2017 | Goldman Sachs Group, Inc. (The) | Set Price Target | Sell | GBX 3,900 | |
| 8/2/2017 | Shore Capital | Reiterated Rating | Hold | | |
| 8/1/2017 | Jefferies Group LLC | Lower Price Target | Hold | GBX 4,900 -> GBX 4,400 | |
| 7/28/2017 | Morgan Stanley | Downgrade | Equal Weight | GBX 5,600 -> GBX 4,700 | |
| 7/28/2017 | Beaufort Securities | Downgrade | Sell | GBX 3,900 | |
| 7/28/2017 | Kepler Capital Markets | Set Price Target | Buy | GBX 5,200 | |
| 7/28/2017 | Citigroup Inc. | Reiterated Rating | Buy | GBX 6,000 | |
| 7/28/2017 | Berenberg Bank | Set Price Target | Buy | GBX 5,500 | |
| 7/28/2017 | Credit Suisse Group | Lower Price Target | Neutral | GBX 5,000 -> GBX 4,700 | |
| 7/27/2017 | S&P Global | Set Price Target | Neutral | GBX 4,500 | |
| 7/27/2017 | Liberum Capital | Reiterated Rating | Buy | GBX 5,500 | |
| 7/21/2017 | BNP Paribas | Reiterated Rating | Neutral | | |
| 4/28/2017 | Sanford C. Bernstein | Set Price Target | Neutral | GBX 4,736 | |
| 3/23/2017 | Societe Generale | Reiterated Rating | Buy | | |
| 2/28/2017 | Bryan, Garnier & Co | Reiterated Rating | Buy | GBX 5,400 | |
| 6/24/2016 | Independent Research GmbH | Set Price Target | Sell | GBX 3,650 | |
| 5/10/2016 | Oddo Securities | Reiterated Rating | Buy | GBX 5,400 | |
| 5/5/2016 | Charles Stanley | Upgrade | Strong-Buy | | |
| 3/24/2016 | Natixis | Reiterated Rating | Neutral | GBX 4,456 | |
| 3/23/2016 | Nomura | Lower Price Target | Hold | GBX 4,880 -> GBX 4,350 | |
| 2/12/2016 | Baader Bank | Reiterated Rating | Hold | GBX 4,400 | |
| 2/9/2016 | AlphaValue | Upgrade | Buy | GBX 4,640 | |
| 2/4/2016 | S&P Equity Research | Set Price Target | Neutral | GBX 4,500 | |
| 2/2/2016 | Handelsbanken | Reiterated Rating | Accumulate | GBX 5,220.30 | |
| 1/28/2016 | Pareto Securities | Reiterated Rating | Sell | GBX 3,855.35 | |
| 1/27/2016 | Swedbank | Reiterated Rating | Buy | GBX 5,115.47 | |
| 1/13/2016 | Nordea Equity Research | Reiterated Rating | Hold | GBX 4,698.35 | |
(Data available from 8/16/2015 forward)
Earnings History for AstraZeneca plc (LON:AZN)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for AstraZeneca plc (LON:AZN)Current Year EPS Consensus Estimate: $3.76 EPS
Dividend History by Quarter for AstraZeneca plc (LON AZN)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 7/27/2017 | | GBX 68.90 | 1.35% | 8/10/2017 | 8/10/2017 | 9/11/2017 |
| 2/2/2017 | | GBX 150.20 | 3.52% | 2/16/2017 | 2/16/2017 | 3/20/2017 |
| 7/28/2016 | | GBX 68.70 | 1.37% | 8/11/2016 | 8/11/2016 | 9/12/2016 |
| 2/4/2016 | | GBX 131 | 3.16% | 2/18/2016 | 2/18/2016 | 3/21/2016 |
| 7/30/2015 | | GBX 57.50 | 1.33% | 8/13/2015 | 8/13/2015 | 9/14/2015 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for AstraZeneca plc (LON:AZN)Insider Trades by Quarter for AstraZeneca plc (LON:AZN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/27/2017 | Nazneen Rahman | Insider | Buy | 39 | GBX 4,370 | £1,704.30 | |
| 10/27/2015 | Courtois,Jean-Philippe | Insider | Buy | 900 | GBX 4,423 | £39,807 | |
| 8/28/2015 | Soriot,Pascal | Insider | Buy | 76,300 | GBX 3,960 | £3,021,480 | |
| 5/7/2015 | Marc Dunoyer | Insider | Buy | 10,000 | GBX 4,397 | £439,700 | |
| 4/30/2015 | Ann Cairns | Insider | Buy | 1,100 | GBX 4,455 | £49,005 | |
| 4/29/2015 | Shriti Vadera | Insider | Buy | 3,500 | GBX 4,563 | £159,705 | |
| 4/28/2015 | Graham Chipchase | Insider | Buy | 1,100 | GBX 4,606 | £50,666 | |
| 4/27/2015 | Bruce Burlington | Insider | Buy | 600 | GBX 4,662 | £27,972 | |
(Data available from 1/1/2013 forward)
Headline Trends for AstraZeneca plc (LON:AZN)
Latest Headlines for AstraZeneca plc (LON:AZN)
| Source: |
|
| Date | Headline |
|---|
 | BRIEF-Astrazeneca says non-exec director Burlington to retire
www.reuters.com - August 16 at 3:19 AM |
 | AstraZeneca plc (AZN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 15 at 6:50 AM |
 | Edited Transcript of AZN.L earnings conference call or presentation 27-Jul-17 12:30pm GMT
finance.yahoo.com - August 13 at 3:55 PM |
| Brexit Is Quietly Killing Science
finance.yahoo.com - August 8 at 1:36 AM |
 | Ex-Dividend Reminder: Wal-Mart Stores, Nexstar Media Group and AstraZeneca - Nasdaq
www.nasdaq.com - August 7 at 3:24 PM |
 | 3 High-Yield Stocks for Aggressive Investors
www.fool.com - August 7 at 2:26 PM |
| AstraZeneca Takes a Long Shot on Lung Cancer Drug Study
finance.yahoo.com - August 7 at 1:54 AM |
| AstraZeneca plc: Buy the Dip? - Motley Fool
www.fool.com - August 4 at 4:40 PM |
| Why AstraZeneca plc Stock Broke Down in July - Motley Fool
www.fool.com - August 4 at 4:40 PM |
| Why AstraZeneca plc Stock Broke Down in July
www.fool.com - August 4 at 10:51 AM |
| AstraZeneca plc: Buy the Dip?
www.fool.com - August 3 at 8:22 PM |
 | AstraZeneca Stages Major Lung Cancer Comeback - Seeking Alpha
seekingalpha.com - August 3 at 3:05 AM |
| AstraZeneca Gets The Bad News - Seeking Alpha
seekingalpha.com - August 2 at 10:03 PM |
| AstraZeneca Plc :AZN-GB: Earnings Analysis: Q2, 2017 By the Numbers : August 2, 2017
finance.yahoo.com - August 1 at 11:24 PM |
| Pre-Market Most Active for Jul 31, 2017 : SNI, DISCA, SNAP, BTI, RATE, DISCK, AZN, X, FEYE, UMC, TVIX, USLV - Nasdaq
www.nasdaq.com - July 31 at 4:25 PM |
 | AstraZeneca's Imfinzi gets sped-up FDA process - MarketWatch
www.marketwatch.com - July 31 at 4:25 PM |
| AstraZeneca plc (AZN) Given a GBX 5,500 Price Target at Berenberg Bank
www.americanbankingnews.com - July 30 at 6:35 PM |
| AstraZeneca plc's (AZN) Buy Rating Reiterated at Citigroup Inc.
www.americanbankingnews.com - July 30 at 2:08 PM |
| Kepler Capital Markets Analysts Give AstraZeneca plc (AZN) a GBX 5,200 Price Target
www.americanbankingnews.com - July 30 at 12:50 PM |
| AstraZeneca plc (AZN) PT Lowered to GBX 4,200
www.americanbankingnews.com - July 30 at 12:15 PM |
| Beaufort Securities Lowers AstraZeneca plc (AZN) to Sell
www.americanbankingnews.com - July 29 at 11:17 PM |
| Morgan Stanley Downgrades AstraZeneca plc (LON:AZN) to Equal Weight
www.americanbankingnews.com - July 29 at 10:34 PM |
| AstraZeneca: Will Pfizer Come Knocking Again? - Seeking Alpha
seekingalpha.com - July 29 at 3:57 PM |
| What's Next for AstraZeneca and Its Dividend?
finance.yahoo.com - July 29 at 3:57 PM |
| Moody's takes negative outlook on AstraZeneca's debt - Nasdaq
www.nasdaq.com - July 28 at 5:35 PM |
| AstraZeneca (AZN) Beats on Q2 Earnings, Falls on Failed Study
finance.yahoo.com - July 28 at 5:35 PM |
| [$$] AstraZeneca climbs after cancer drug reassessment
finance.yahoo.com - July 28 at 5:35 PM |
| Zeneca Wilmington Inc. -- Moody's changes outlook on AstraZenaca's A3 rating to negative; affirms ratings
finance.yahoo.com - July 28 at 5:35 PM |
| Moody's takes negative outlook on AstraZeneca's debt
finance.yahoo.com - July 28 at 5:35 PM |
| AstraZeneca plc (AZN) Insider Buys £1,704.30 in Stock
www.americanbankingnews.com - July 28 at 10:39 AM |
| AstraZeneca Plc's (AZN) CEO Pascal Soriot on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - July 27 at 9:47 PM |
| [$$] AstraZeneca Shocker Reminds Investors Miracle Drugs Are No Remedy for Risk
finance.yahoo.com - July 27 at 9:47 PM |
| [$$] AstraZeneca Faces Major Setback Over Cancer Drugs
finance.yahoo.com - July 27 at 9:47 PM |
| Mighty AstraZeneca Takes a Lickin' on Failed Mystic Trial
finance.yahoo.com - July 27 at 9:47 PM |
| AstraZeneca plc (AZN) Given a GBX 4,500 Price Target by S&P Global Analysts
www.americanbankingnews.com - July 27 at 4:05 PM |
 | AstraZeneca plc (ADR) (AZN) Stock Tanks on Lung Cancer Drug Disappointment
investorplace.com - July 27 at 12:10 PM |
| AstraZeneca plc to Issue Dividend of GBX 68.90 (AZN)
www.americanbankingnews.com - July 27 at 11:16 AM |
 | Why Is AstraZeneca Sinking Today?
feeds.benzinga.com - July 27 at 10:20 AM |
| AstraZeneca plc (AZN) Given a GBX 5,150 Price Target at UBS AG
www.americanbankingnews.com - July 27 at 6:20 AM |
| Is Lower Revenue in the Cards for AstraZeneca’s 2Q17?
finance.yahoo.com - July 26 at 9:59 PM |
 | AstraZeneca Receives EU Approval For Faslodex Breast Cancer Drug
www.morningstar.co.uk - July 26 at 4:57 PM |
| AstraZeneca plc (AZN) Rating Reiterated by J P Morgan Chase & Co
www.americanbankingnews.com - July 22 at 12:18 PM |
| AstraZeneca plc (LON:AZN) Receives "Neutral" Rating from BNP Paribas
www.americanbankingnews.com - July 21 at 8:16 AM |
| AstraZeneca plc (AZN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 21 at 7:36 AM |
| Chaos At AstraZeneca - Seeking Alpha
seekingalpha.com - July 19 at 10:33 PM |
| AstraZeneca plc (LON:AZN) to Release Earnings on Wednesday
www.americanbankingnews.com - July 19 at 2:58 AM |
| AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise - Nasdaq
www.nasdaq.com - July 17 at 9:39 PM |
| AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise
finance.yahoo.com - July 17 at 9:38 PM |
| CEO departures not always bad for companies: Cramer
finance.yahoo.com - July 17 at 9:38 PM |
 | AstraZeneca Shares Slump On Reports Teva Courting CEO Pascal Soriot - TheStreet.com
www.thestreet.com - July 14 at 11:13 PM |
AstraZeneca plc (AZN) Chart for Wednesday, August, 16, 2017
